Bristol Pravachol Promotion Cited For Misleading Superiority Claim By FDA
Executive Summary
Bristol-Myers Squibb's Pravachol (pravastatin) physician-directed promotions contain unsubstantiated superiority safety claims over other cholesterol-lowering drugs, FDA's ad division maintains.
You may also be interested in...
Bristol Pravachol Ads Broaden Indication, FDA Warning Letter Says
FDA is asking Bristol-Myers Squibb to correct Pravachol advertising claims that the agency says broadens the indication and patient populations for which the cholesterol-lowering agent is approved
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011